Q4 2025 Evaxion A/S Earnings Call Transcript
Key Points
- Evaxion AS (EVAX) reported significant progress in 2025, including a collaboration with MSD and the Gates Foundation, enhancing their infectious disease portfolio.
- The company presented positive two-year Phase 2 data for their EVX-01 cancer vaccine, showing a high objective response rate of 75% and a complete response rate of 25% in advanced melanoma patients.
- Evaxion AS (EVAX) has extended its cash runway into the second half of 2027, thanks to successful financing activities and strategic partnerships.
- The AI-Immunology platform received recognition from the Galien Foundation for its advances in human health, highlighting its innovative approach.
- The company is exploring new applications of its AI-Immunology platform in autoimmune diseases, potentially expanding its market reach.
- MSD chose not to exercise its option over the EVX-B2 candidate for gonorrhea, indicating potential challenges in advancing this program.
- Despite progress, Evaxion AS (EVAX) faces the challenge of translating its technical strengths into meaningful transactions with large-cap pharma companies.
- The company acknowledges that it is not positioned to take too many products further into the clinic, which may limit its ability to independently advance its pipeline.
- There is uncertainty regarding the regulatory path and partner interest for the EVX-04 program, as ERVs are a novel and different approach.
- Evaxion AS (EVAX) is still in the early stages of applying its AI-Immunology platform to autoimmune diseases, with no specific indications or candidates yet validated.
/-
Thank you for joining us for Evaxion's business update following the reporting of our 2025 full year financial results yesterday. And apologies that this call is 24 hours later than we anticipated for technical reasons.
We are delighted to be here today. My name is Helen Tayton-Martin, and I am honored to be leading this call for the first time as Evaxion's CEO.
We move to the first slide. Okay. So on today's call, we will review the achievements of 2025 and touch on the milestones we anticipate for 2026. Our Chief Scientific Officer, Birgitte Rono, will then walk through our key R&D updates for the year, including the latest innovations from our AI-Immunology platform, after which our CFO, Thomas Schmidt, will walk through our 2025 financial results before we close with a few concluding remarks and take questions.
Right. Moving to the next slide. And of course, our comments and presentation today may contain forward-looking statements and all participants on today's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
